Perioperative Care for Jehovah's Witnesses


  • Patients may decline blood products for religious reasons (most commonly Jehovah's Witnesses) or because of concerns about the risks of allogeneic transfusion

  • Jehovah's Witnesses are a Christian-based religious movement: ~8.8 million members worldwide, ~145,000 in the UK
  • They believe blood represents a sacred life force, and taking the blood of another into the body violates God's word
  • Giving treatment to a patient with capacity without their consent is assault and an infringement of their human rights

  • Care is built around patient blood management (PBM), which has three pillars:
    • Optimise pre-operative haemoglobin
    • Reduce peri-operative blood loss
    • Enhance physiological tolerance of anaemia

As of September 2026, acceptance of the main blood components is a matter of individual conscience for Jehovah's Witnesses, so never assume refusal and ask each patient about each product.


March 2026: autologous blood

  • The Governing Body announced that use of a patient's own blood is a matter of individual conscience
  • This includes pre-operative autologous donation, storage and later reinfusion, which was previously unacceptable

September 2026: primary blood components

  • Whether to accept the four primary components from another person (red cells, white cells, platelets and plasma) is now a matter of individual conscience
  • Members may also decide whether to donate blood for use as components or fractions
  • Members choosing to accept components no longer risk being expelled from the congregation
  • Transfusion of whole blood remains prohibited

Implications for practice

  • Almost all UK transfusions use separated components rather than whole blood, so many Witnesses may now accept the majority of routine transfusion products
  • Establish directly which components and techniques each patient will accept or refuse
  • Advance decisions completed before the change may no longer reflect the patient's wishes so review them with the patient and complete a new one if needed
  • Some patients will continue to decline all blood products and a capacitous decision must still be respected
  • The blood conservation principles below remain relevant to all patients, whatever they accept


Not acceptable Individual conscience Generally acceptable
Whole blood from another person Red cells* Crystalloids and synthetic colloids
White cells* Recombinant EPO
Platelets* Recombinant factor VIIa
Plasma (FFP)* Hypervolaemic haemodilution (no blood removed)
Fractions: albumin, immunoglobulins, clotting factor concentrates, cryoprecipitate, fibrinogen concentrate
Pre-operative autologous donation and storage**
Cell salvage
Acute normovolaemic haemodilution
Haemodialysis and plasmapheresis
Cardiopulmonary bypass and ECMO
Epidural blood patch

  • *Previously unacceptable; individual conscience since September 2026
  • **Previously unacceptable; individual conscience since March 2026

  • Acceptability varies between individuals, so discuss and document each item before anaesthesia
  • Patients can liaise with the Hospital Liaison Committee for Jehovah's Witnesses if they wish

Adults

  • Autonomy is a core principle and a capacitous refusal of life-saving treatment must be respected
  • The Mental Capacity Act 2005 states that patients aged ≥16 years are assumed to have capacity unless proven otherwise
  • A patient must not be assumed to lack capacity simply because their decision appears unwise

Advance decisions

  • Can be made by an adult with capacity (≥18 years in England and Wales, ≥16 years in Scotland) to refuse treatment should they lose capacity in future
  • An advance decision refusing life-sustaining treatment is only valid if:
    • It is in writing
    • It is signed by the patient (or by another person in their presence and at their direction)
    • The signature is made or acknowledged in the presence of a witness, who also signs in the patient's presence
    • It states that it applies even if the patient's life is at risk
  • Can be withdrawn at any time by a patient with capacity and withdrawal does not need to be in writing

Children

  • A child is anyone under 18 years (Children Act 1989)
  • 16 to 17 year olds can consent and are assumed to have capacity
  • Those ≤15 years may consent if Gillick competent for that specific decision

  • A Gillick competent child's consent cannot be overridden by those with parental responsibility
  • However, a child's refusal can be overridden by a person with parental responsibility; seek legal advice

  • If both child and parents refuse essential treatment:
    • Ensure all alternatives have been explored
    • As a last resort apply to the High Court for a Specific Issue Order (Section 8, Children Act 1989) via hospital legal services, with the support of ≥2 consultants; parents should be notified
    • In an emergency, treat in the child's best interests if two consultants agree that all alternatives have been exhausted

Perioperative Management of the Patient who Declines Blood Products


Identification and planning

  • Identify patients as early as possible via pre-assessment
  • Multidisciplinary planning including consultant surgeon, anaesthetist and haematologist ± Hospital Liaison Committee representatives if the patient wishes
  • Consider lower blood loss alternatives e.g. minimally invasive or endovascular techniques
  • In some cases the risk of haemorrhage may outweigh the benefit of the procedure so use shared decision-making and document all discussions
  • Elective cases should be on weekdays with direct consultant anaesthetic and surgical involvement
  • If cell salvage is acceptable, ensure it is available on the day

Consent and documentation

  • Discuss with the patient in private so they are not under pressure from family or church members
  • Have a frank and honest discussion about the consequences of refusing blood products
  • Complete a written advance decision specifying which products and interventions are acceptable or unacceptable (many centres have a proforma)
  • Review any community advance decision against legal requirements and the 2026 changes and if in doubt complete a new one

Potential consequences of refusing transfusion
Haemodynamic instability and organ failure
Requirement for mechanical ventilation and unplanned ICU admission
Delayed wound healing and ↑ wound infection
Prolonged hospital stay
↑ mortality

Optimisation

  • Take a medical and drug history for coagulation disorders and drugs impairing haemostasis
  • Stop antiplatelet and anticoagulant drugs where clinically appropriate

  • Optimise red cell mass through investigation of anaemia and correction of deficiencies
    • Offer iron therapy if Hb <130 g/L, and delay elective surgery until achieved where possible
    • Oral iron for iron deficiency, low iron stores or iron sequestration
    • IV iron if oral response is inadequate, oral iron cannot be absorbed or taken, or surgery is within 4 weeks
    • Recombinant EPO: ↑ Hb and ↓ transfusion requirement but requires specialist advice and only once nutritional deficiencies are excluded or treated
  • Pre-operative autologous donation may now be an option for some patients

Emergency surgery

  • Same principles as elective surgery but with time constraints
  • If the patient lacks capacity, efforts must be made to find an advance decision (the GP may have access)
  • If no valid advance decision exists, act in the patient's best interests (see major haemorrhage section)

General

  • MDT review on the day to ensure a valid advance decision is immediately available
  • Highlight the patient's wishes and the blood conservation plan at the WHO team brief

Anaesthetic strategies

  • Temperature monitoring and active warming: hypothermia ↓ coagulation enzyme activity and platelet function
  • Ventilation: avoid hypercapnia (vasodilation) but also excessive airway pressures (↓ venous return, ↑ venous congestion)
  • Positioning to avoid venous pooling e.g. avoid IVC compression when prone
  • IV tranexamic acid for any procedure with a risk of moderate blood loss, unless contraindicated
  • Neuraxial anaesthesia: sympathetic block reduces arterial & venous pressures, contributing to 335ml less blood loss and a 15% ↓ in red cell transfusion vs GA in major abdominal and lower limb surgery
  • Limit phlebotomy and use paediatric blood bottles

Permissive hypotension

Advantages Disadvantages
↓ blood flow to the surgical field Organ hypoperfusion: myocardial, renal and cerebral injury
~287 ml ↓ in mean blood loss in orthopaedic surgery Mixed evidence; benefit outside orthopaedics not demonstrated
↓ transfusion requirement Avoid in coronary or cerebrovascular disease, and in Caesarean delivery

Cell salvage

  • ↓ post-operative anaemia and allogeneic transfusion (by 37 to 49% in cardiac, vascular and orthopaedic surgery)
  • Consider when blood loss may exceed 500 ml
  • If blood loss is hard to predict, use 'collect only' mode and process only if bleeding becomes significant
  • Many Witnesses accept the standard set-up although some request a continuous circuit, achieved by connecting the reinfusion bag to a cannula via a saline-primed giving set run slowly until processed blood is available

  • Contraindictions
    • There are no absolute contraindications
    • Contamination with tumour cells, bowel contents or infected fluid although benefits may still outweigh risks

Haemodilution

  • Acute normovolaemic haemodilution (ANH):
    • 10 to 20% of estimated blood volume withdrawn before induction into an anticoagulated reservoir and replaced with crystalloid or colloid
    • Blood lost during surgery has a lower haematocrit, so fewer red cells are lost; withdrawn blood is reinfused at the end
    • ~26% ↓ risk of red cell transfusion, although benefit is likely overestimated
  • Hypervolaemic haemodilution: fluid infused before surgery without removing blood; simpler, but only case reports and small trials support it

Surgical strategies

  • Meticulous haemostasis by an experienced surgeon is probably the most important factor
  • Diathermy
  • Topical haemostatic agents: shorten time to haemostasis but do not ↓ clinically relevant blood loss or transfusion

  • Arterial tourniquets: ↓ intra-operative loss and improve the surgical field, but no difference in overall blood loss or transfusion
  • Complications
    • Systemic: circulatory overload or cardiovascular collapse (sudden changes in SVR), hypercapnia, hyperkalaemia, ↑ VTE risk, altered drug kinetics
    • Local: nerve, vascular, muscle and skin injury

  • Close monitoring for bleeding with a low threshold for escalation ± HDU
  • Handover should specify consent boundaries, intra-operative events and the plan, including timing of VTE prophylaxis

  • Minimise ongoing blood loss:
    • Normothermia
    • Correct coagulopathy
    • Consider a repeat dose of IV tranexamic acid if concern about bleeding (little evidence over a single dose)
    • Minimise blood sampling
  • NSAIDs are unlikely to cause bleeding and can be continued unless otherwise contraindicated
  • Optimise oxygen delivery and nutrition to support endogenous haemopoiesis

Initial management

  • Medical management proceeds alongside medicolegal steps, with ≥2 consultant anaesthetists present and contemporaneous documentation
  • As for any major haemorrhage: call for help, inform theatre team, check IV access, warmed fluids and active warming
  • Point-of-care testing (blood gas, TEG/ROTEM) and laboratory calcium and fibrinogen using paediatric bottles
  • Replace calcium and give tranexamic acid
  • Consultant-led surgical haemostasis; consider interventional radiology for arterial bleeding or difficult access
  • Early haematology input to guide acceptable products

Blood product alternatives


Agent Key points
Desmopressin 0.3 μg/kg IV or SC; ↑ factor VIII and vWF; little evidence it ↓ surgical blood loss; risks thrombosis, fluid retention and hyponatraemia
Prothrombin complex concentrate Reversal of vitamin K antagonists; plasma-derived so may not be acceptable
Recombinant factor VIIa Not plasma-derived so may be acceptable; UK licence limited to severe PPH, congenital factor VII deficiency and rare bleeding disorders; high thrombotic risk
Fibrinogen concentrate Plasma-derived; hypofibrinogenaemia is common in major (especially obstetric) haemorrhage; systematic reviews show no overall benefit

Medicolegal steps: patient lacks capacity

  • E.g. under general anaesthesia
  • A valid advance decision must be honoured
  • If no advance decision, act in the patient's best interests:
    • Make every effort to avoid transfusion if there is reason to believe the patient would refuse
    • Giving blood products is justified to avoid death or serious harm
  • Involve legal services if there is doubt about the existence or validity of an advance decision, or dispute about best interests

Medicolegal steps: conscious patient

  • Consent may be revisited during an evolving crisis; a patient with capacity can revoke an advance decision at any time
  • Beware coercion (or perceived coercion) and cognitive impairment from sedatives or haemorrhage
  • A suggested mid-crisis approach:
    • Optimise the 'environment of autonomy' by managing pain and distress
    • Assess capacity and ask if the patient feels able to make a choice
    • Ask the patient to state their choice and articulate its consequences
    • Two healthcare providers present; document clearly
  • This practice remains controversial and should be managed with caution

Antenatal

  • Consultant-led obstetric care and referral to a high-risk obstetric anaesthesia clinic
  • Optimise Hb, establish acceptable therapies and complete a valid written advance decision
  • Identify PPH risk factors to inform planning

Intrapartum

  • Notify the consultant obstetrician and anaesthetist on arrival in labour; both should be present for instrumental or Caesarean delivery in theatre
  • Early anaesthetic review: confirm advance decision and additional risk factors
  • Wide-bore IV access and active management of the third stage

Caesarean delivery

  • Experienced surgical and anaesthetic teams; plan timely uterotonics and consider routine tranexamic acid
  • Permissive hypotension is not appropriate
  • Cell salvage recommended if acceptable:
    • Separate suction for amniotic fluid is no longer considered essential
    • Leucocyte depletion filters do not remove all amniotic fluid components and can slow reinfusion to ~40 ml/min

Major obstetric haemorrhage

  • Follow the principles above alongside standard major obstetric haemorrhage guidelines: prompt escalation, early fluid resuscitation, uterotonics and tranexamic acid
  • Fibrinogen <2 g/L strongly predicts progression to major obstetric haemorrhage (normal at term may be 4 to 7 g/L)

Epidural blood patch

  • May be unacceptable to some Witnesses
  • A continuous circuit technique has been described: IV catheter connected to the Tuohy needle via sterile extension tubing and a four-way tap, allowing aspiration and injection
  • Requires a Luer Tuohy needle, so may not be possible in centres using NRFit devices

  • Patients may temporarily lack capacity: apply the medicolegal principles above
  • Acceptability of extracorporeal circuits (RRT, plasma exchange, ECMO) varies and may not have been considered in a community advance decision
  • If unclear, engage medicolegal services and the patient's family
  • Non-blood circuit primers may improve acceptability